The integration of SoloSmart with the Glooko platform will allow users to see the correlation between injected insulin dose and blood glucose values. Credit: Glooko, Inc.

Glooko has entered a global collaboration with Sanofi to integrate the SoloSmart device into the Glooko platform, which will provide support for healthcare professionals and individuals with diabetes.

SoloSmart is a single add-on connected device that has been developed for use with the SoloStar and DoubleStar insulin injection pens.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

These pens are used to capture data regarding insulin dose as well as the date and time of injection, which can then be visualised in the Glooko app.

The app also allows patients to share the data with their healthcare specialists for connected care in diabetes management.

Sanofi’s aim is to increase the availability of its digital solutions to people with diabetes through Glooko’s global footprint of more than 8,000 clinics.

Currently, the SoloSmart cap is being integrated into the Glooko platform. It is planned to be gradually launched across several countries, starting later in the year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Glooko stated that the combined solution will be offered in English as well as local languages.

Glooko CEO Russ Johannesson said: “We are very pleased to announce our partnership with Sanofi, as this agreement represents the first substantial digital health collaboration between our two companies.

“Glooko is the first global diabetes data management platform to launch with SoloSmart, something our team is particularly proud of.

“This will allow us to further expand our global reach, aiming to provide best-in-class technologies that can benefit the lives of people with diabetes.”

After completing the integration, users of the SoloStar and DoubleStar pens will be able to add insulin dose and time tracking to Glooko’s functionality.

This integration will allow users to see the correlation between injected insulin doses and blood glucose values.

The insulin-tracking data can also be connected to the Glooko mobile app’s other key features, such as blood pressure, exercise metrics, food tracking and weight.

Sanofi Digital Healthcare global head Jared Josleyn said: “At Sanofi, we believe that we will deliver value to people living with diabetes by building an ecosystem with local and global partners.

“With Biocorp, SoloSmart’s manufacturer, Glooko, a leading digital health solution that supports patients and health care partners, and local partners, we aim to improve daily management for individuals living with diabetes.”